|
In the pursuit of delivering more personalized medicine, advances in pharmacogenetics have led to an era of companion diagnostics. Click here for a list of targeted drugs and biomarker assays.
ABL Gene Mutation Analysis
In patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML), the ABL gene mutation assay developed by MPLN detects an individual's resistence to the kinase inhibitor, Gleevec®.
BRAF Testing
BRAF testing identifies the subset of colorectal cancer patients who do not have a mutated KRAS gene, yet still do not respond to EGFR therapy. Testing for KRAS and BRAF V600E mutations provides a comprehensive analysis when evaluating a patient for anti-EGFR therapy.
KRAS Mutation Test
The KRAS mutation test is used to identify patients with colorectal cancer who are most likely to show limited clinical reponse to EGFR inhibitors cetuximab (Erbitux®) and panitumumab (Vectibix®).
UGT1A1 Genotyping
The Invader® UGT1A1 Molecular Assay (Hologic®) is a one-time screening test for newly-diagnosed colorectal cancer patients used to detect variations in the UGT1A1 gene that influences an individual's ability to metabolize irinotecan (Camptosar®).
Warfarin Sensitivity Test
The Warfarin Sensitivity Test (Verigene® by Nanosphere, Inc.) detects and genotypes the *2 and *3 alleles of the CYP2C9 gene and a single polymorphism (1173C>T) in the VKORC1 gene to assist physicians with prescribing the correct dosage of warfarin (Coumadin®).
Laboratory Services in One Location
Anatomic Pathology | Immunohistochemistry | Immunomagnetic Cell Capture (CellSearch)
Flow Cytometry | Cytogenetics | Fluorescence in situ hybridization (FISH) | Molecular Diagnostics
|
